Life Sciences and Healthcare

FDA efficacy recommendations vary for hypogonadotropic hypogonadism drugs

New draft industry guidance from the U.S. Food and Drug Administration (FDA) underscores the importance of randomized, double-blind, placebo-controlled trials to establish the efficacy of drugs to treat male hypogonadotropic hypogonadism when it is caused by obesity or another acquired condition. The draft guidance also asserts the potential importance of patient-reported outcome (PRO) instruments to […]

Pulse check: reduce discharged not final billed

Does your organization struggle with getting bills out the door within a timely manner? You are not alone. Many organizations have identified discharged not final billed (DNFB) as an opportunity within their organization for 2018. It is already difficult for providers to get reimbursed on time because of the ever-growing impact of denials. Learning how […]

Digital Medicine: The Connection Between Pharma and Medical Devices

In recent years, two major healthcare sectors—pharmaceuticals and medical devices—have become increasingly connected through advancements made in digital medicine. Digital medicine is the application of technology in healthcare, not just to better understand and track physiological systems, but also to process the vast amounts of data generated by medical devices that can collect patient data, […]

5 things to know about the joint commission’s new stroke certificate

With May being American Stroke Month, the American Stroke Association and American Heart Association are placing a special emphasis on broadcasting prevention strategies and promoting symptom awareness. Though hospitals and health systems are similarly concentrating on prevention efforts, many are also working to gain The Joint Commission’s new stroke certificate: Thrombectomy-Capable Stroke Center. Created in collaboration with ASA and AHA, […]

FDA approval of first-in-class Aimovig set to transform the migraine market

This article is part of an ongoing blog series profiling the12 new, game-changing drugs predicted to achieve blockbuster status by 2022 in the 2018 edition of Drugs to Watch, the annual industry forecast and analysis from Clarivate Analytics. Read the full Drugs to Watch report here or follow the series for the latest updates. Approval […]

Why is life sciences data integration so hard?

A new analysis and guide from the Life Sciences data integration team at Clarivate Analytics asks the question, “Why is data integration so hard?” The paper looks at the many reasons biopharma companies might want to integrate their vast and often mixed storehouses of data – revisiting an old drug program in light of new […]